Found 1 Presentation For Request "1004p"
1004P - Efficacy and safety of anlotinib monotherapy or combination therapy as second-line therapy in EGFR-wild-type non-small cell lung cancer (NSCLC) patients
- Junhui Guo (Zhengzhou, China)
Abstract
Background
Docetaxel is a standard second line treatment in advanced NSCLC, but the treatment effect is limited. Anlotinib was a novel oral multi-targeted tyrosine kinase inhibitor for tumor angiogenesis and proliferation, which had been licensed for treatment of considerable malignancies in China. However, limited evidence exists to show the efficacy of anlotinib monotherapy or combination therapy for patients who have progressed after first line therapy. Therefore, a retrospective study was conducted to assess whether anlotinib combination therapy could improve efficacy compared with anlotinib monotherapy therapy as second line therapy for NSCLC patients.
Methods
Pts with advanced NSCLC who received at least 2 cycles of anlotinib (8∼12mg, po, d1∼14, q3w) were recruited in this study in Henan Province Hospital of TCM. Clinical efficacy and survival data was summarized, adverse events were documented retrospectively. The primary endpoint was progression-free survival (PFS). Secondary endpoints were objective response rate (ORR), disease control rate (DCR) and safety.
Results
From Jan 2020 to Aug 2021, a total of 20 eligible pts with EGFR-wild-type NSCLC were screened. Among them, 6 pts received anlotinib monotherapy and 14 were treated with anlotinib with or without anti-PD-1/chemotherapy. With a median follow-up of 8.4 months, combination therapy group showed longer PFS compared with monotherapy group (8.40m vs. 5.25m, HR = 0.72). In addition, ORR was 21.4% (3/14) in the combination therapy group versus 16.7% (1/6) in the monotherapy group and the DCR was 87.5% (14/16) in the combination therapy group versus 66.7% (4/6) in the monotherapy group. The safety profile suggested that the most common drug-related adverse events were decreased appetite, thrombocytopenia, hypertension, diarrhea, hand-foot syndrome, proteinuria and there were no ≥Grade 3 toxicities.
Conclusions
Anlotinib with or without anti-PD-1/chemotherapy resulted in longer PFS and higher ORR and DCR as second line therapy in EGFR-wild-type advanced NSCLC patients. These findings need to be further explored by randomized controlled studies.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.